FDA Meeting Types for Biosimilar Products
For biosimilar developers, early and successful interactions with FDA are crucial to ensuring that the health authority is well-informed and supports your planned development path. Meeting with FDA provides sponsors the opportunity to get feedback on critical development issues, which can reduce costs, regulatory risk, and time to approval. Download the infographic to learn more about the different meeting types under BsUFA for biosimilar products, when they apply, examples of, and the timing parameters of each meeting type.
downloadExplore Our Key Related Services
Please fill out this form to access your resource.